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In Review
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For over 20 years, studies have tried to measure the association between the duration of
untreated psychosis (DUP) and changes in brain morphology. A hypothesis that untreated
psychosis is neurotoxic has been postulated, but the mechanisms of that toxicity have not
been described. We re-analyzed papers collected for a systematic review to extract data on
the hypotheses that have been generated on the potential mechanisms by which DUP could
impact brain morphology in first-episode psychosis. Dopaminergic hyperactivity, prolonged
hypothalamic–pituitary–adrenal activation, and persistent activity of catecholamines have
been hypothesized as mechanisms to explain these associations. However, the question
remains as to whether the observed structural changes are permanent or may be reversed
via antipsychotic treatment.
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Le rôle de la psychose non traitée dans la neurodégénérescence :
une revue des mécanismes hypothétiques de neurotoxicité dans le
premier épisode de psychose
Depuis plus de 20 ans, les études tentent de mesurer l’association entre la durée de la
psychose non traitée (DPNT) et les changements de la morphologie du cerveau. Une
hypothèse a été émise selon laquelle la psychose non traitée est neurotoxique, mais les
mécanismes de cette toxicité n’ont pas été décrits. Nous avons ré-analysé les articles
recueillis pour une revue systématique afin d’extraire des données sur les hypothèses
générées sur les mécanismes potentiels par lesquels la DPNT pourrait avoir une influence
sur la morphologie du cerveau dans un premier épisode de psychose. L’hyperactivité
dopaminergique, l’activation hypothalamo-hypophyso-surrénalienne prolongée, et l’activité
persistante des catécholamines ont été supposées être des mécanismes pour expliquer
ces associations. Cependant, il reste à savoir si les changements structurels observés sont
permanents ou s’ils peuvent être inversés par un traitement antipsychotique.

Is there something about being psychotic that
is toxic to the individual, beyond the immediate
psychotic episode? . . . some patients are left with
a damaging residual if a psychosis is allowed to
proceed unmitigated. While psychosis is
undoubtedly demoralizing and stigmatizing,
it may also be biologically toxic.—Wyatt1, p 347
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I

n a review published in 1991 examining the effects of
neuroleptic drugs on the natural course of schizophrenia,
Wyatt1 noted that early administration of antipsychotic
treatment was associated with an improved prognosis
among patients with FEP, a finding that has been replicated
numerous times.2–4 Wyatt used the analogy of ischemic
heart disease to illustrate his point: repeated ischemic
attacks cause cumulative damage that can eventually result
in chronic heart failure, and early treatment of ischemic
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attacks reduces the damage and scarring to the heart
tissue. He argues that prolonged or repeated episodes
of psychosis similarly leave scars on the brain, possibly
via changes in morphology, biochemical alterations, or
damage to neuronal connections.1 This theory has come to
be known as the neurotoxicity hypothesis, and it is one of
several mechanisms used to try and explain the observed
association between a longer DUP and poor outcomes.2–4 It
has also been used to justify early intervention efforts and
involuntary treatment, given their potential for preventing
permanent brain damage.
Fast-forward nearly 25 years and we still do not have a
clear understanding of the mechanisms behind the observed
association between a longer DUP and poor outcomes
among patients with FEP. Irrespective of the mechanism,
early intervention efforts aimed at symptom detection
and comprehensive care during the initial stages of illness
are a worthwhile initiative for improving clinical, social,
and vocational outcomes,5–7 as well as for providing costeffective care.8–10 However, the question of whether untreated
psychosis has a neurotoxic effect on the brain has important
ethical and legal implications for the use of coercive and
involuntary treatment. Indeed, this question remains very
difficult to test empirically, given that confounding factors,
such as treatment with antipsychotics,11–14 cannabis use,15,16
and other lifestyle habits,17 have also been found to be
associated with changes in brain structure.
There have been 2 recent reviews of the literature
specifically investigating the link between DUP and brain
structure (Kelly K Anderson, August 22, 2014, personal
communication).18 The conclusions have been equivocal.
Many of the included studies did not find evidence to support
an association between brain structure and DUP, but the
reviews of the literature suggest that the larger studies with
the best methodologies are more likely to report positive
findings.18 It has also been suggested that there may be a
threshold effect of untreated psychosis, rather than a linear
association, such that the neurotoxic effects of psychosis
may only be observed at longer lengths of DUP.18
There has also been a literature review looking at the
association between DUP and neurocognition.18 Among
the 22 studies reviewed, 6 reported associations between
cognitive measures and DUP: 2 reported worse general
cognitive deterioration with a longer DUP, and the other
4 reported deficits in shifting attention, verbal IQ, visual
and verbal memory, and event-based prospective memory.
However, 16 studies, in which a total of over 2000 patients

Highlights
•

There is some evidence to suggest that the DUP may
have a neurotoxic effect on brain structures in FEP.

•

Dopaminergic (catecholaminergic) hyperactivity and
prolonged HPA activation have been hypothesized as
potential mechanisms to explain these associations.

•

The question that remains is whether the observed
structural changes are permanent or may be reversed
via antipsychotic treatment.

were tested with various measures, did not report any
association between DUP and neurocognition.18
In our paper, we will discuss the mechanisms proposed by
investigators who have empirically tested the neurotoxicity
hypothesis in an effort to explain an association between
untreated psychosis and brain structure. To perform our
review, we used a database of relevant papers that was
produced for a systematic review looking at the association
between untreated psychosis and brain morphology (Kelly
K Anderson, August 22, 2014, personal communication).
The review used MEDLINE, Embase, PsycInfo, and the
Web of Knowledge as search engines. It focused on studies
that included patients with treatment-naive or minimally
treated psychotic disorders in an effort to reduce the
confounding effects of antipsychotics and illness chronicity.
We looked at studies that measured the DUP, which is
the period between the onset of the active symptoms of
psychosis (delusions, hallucinations, or thought disorder)
and the initiation of adequate antipsychotic treatment.19 We
also looked at studies that had measured the DUI, which
is the time between the onset of any psychiatric symptoms
and the initiation of adequate antipsychotic treatment,
which includes both the prodromal period and the period of
active psychosis.19 The literature review and data extraction
methods were based on published guidelines for the conduct
of systematic reviews.20
Evidence for the association between untreated psychosis
and brain structure are presented elsewhere (Kelly K
Anderson, August 22, 2014, personal communication).18
For our review, we identified 9 papers in total where a
positive association between the DUP–DUI and brain
morphology was found. We then extracted the hypothesized
mechanisms proposed in the papers to explain the observed
associations. We aimed to get a sample of the thoughts of
investigators working in this line of research as to how
untreated psychosis may cause damage to brain structures.

Potential Underlying Mechanisms

Abbreviations
DUI

duration of untreated illness

DUP

duration of untreated psychosis

FEP

first-onset psychosis

HPA

hypothalamic–pituitary–adrenal
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Among the 9 studies that demonstrated a positive
association between DUP–DUI and outcome,21–29 only 2 of
the authors proposed specific biological mechanisms that
could potentially underlie structural alterations occurring as
a result of the neurotoxic effects of untreated psychosis.22,24
The authors of both papers proposed a mechanism of
dopaminergic hyperactivity,22,24 whereby the prolonged
www.LaRCP.ca
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elevation of dopamine seen during a psychotic episode
leads to a progressive decline in the volume of neural
structures, especially in regions with a high concentration
of dopamine D2 receptors, such as the caudate nucleus.22
Indeed, dopaminergic agents have been shown to induce
neuronal apoptosis.30 The authors cite evidence showing
that treatment with antipsychotics is associated with an
enlargement in the volume of specific neural structures,31
and this is believed to occur via blockade of the D2
receptors.32,33 Taken together, this evidence begs the question
of whether any observed structural changes associated with
untreated psychosis reflect neuronal injury, rather than
death, that could potentially be reversed with the initiation
of antipsychotic treatment.24
In a similar vein to the mechanism of dopaminergic
hyperactivity, Keshavan et al24 also propose that
neurotoxicity may occur via oxidative injury arising
from persistent catecholaminergic activity, as well as
from prolonged activation of the HPA axis. In both cases,
antipsychotics are proposed to reduce the catecholaminergic
activity and HPA activation, respectively, thereby reducing
the extent of neuronal damage owing to untreated psychosis.
Alternatively, both Lappin et al25 and Malla et al27 raise
the possibility that the observed structural abnormalities
may be a marker for poor premorbid functioning or an
insidious onset of psychotic disorder, consequently leading
to a longer delay in detection and initiation of antipsychotic
treatment. Indeed, there is evidence to suggest that people
who have poor levels of premorbid functioning, especially
during childhood, are more likely to show computerized
tomography scan abnormalities.34 Although other studies
have shown an association between poor premorbid
functioning and the length of the DUP,35 Malla et al27 did
not find a difference in premorbid adjustment between
patients with a longer and shorter DUP, suggesting that this
hypothesis could not explain grey matter deficits observed
in the longer DUP group in their study.

Limited Evidence to Support the
Neurotoxicity Hypothesis

We present the hypotheses from 9 studies that have shown a
link between untreated psychosis and brain morphology.21–29
However, note that there are many additional studies that
have not found evidence of an association between DUP–
DUI and structural abnormalities in FEP (Kelly K Anderson,
August 22, 2014, personal communication).18 The common
criticisms of these negative studies is that they have small
sample sizes and that they include patients who have already
been exposed to antipsychotics. Additionally, most studies
that investigate the validity of the neurotoxicity hypothesis
using measures of neurocognitive functioning do not find
an association with DUP.18
McGlashan36 outlines several reasons why active psychosis
is unlikely to have a biologically toxic effect, specifically:
1) the effect of DUP on outcome plateaus at longer
lengths of treatment delay,
www.TheCJP.ca

2) neuronal degeneration is evident prior to the onset of
the active symptoms of psychosis,
3) there is no evidence to suggest that functional deterioration is cumulative with each relapse, and
4) a lack of evidence of neuronal death observed in postmortem brains of people with schizophrenia.

Limitations of the Literature to Date

The challenge with the discussion on potential mechanisms
of neurotoxicity may, in part, reflect general issues
with the literature, to date, on the association between
untreated psychosis and brain structure. Many studies
have empirically examined this association, but there have
been many methodological problems with this body of
literature. Any rigorous investigation of the neurotoxicity
hypothesis faces many complex methodological questions:
Which brain structures should be considered? What types
of neuroimaging techniques should be used? Does this
imaging technique accurately measure the functional
changes that are seen in psychosis? Are there structural
changes occurring at a microscopic level that current
imaging approaches may not be able to detect in vivo?
Should samples include people with psychosis generally, or
people with schizophrenia specifically, given how difficult
it is to make diagnoses at the first episode? How can we
account for the myriad confounding factors?
In addition to these challenges, the fundamental issue that
has plagued all studies in the field of early psychosis is the
measurement of the DUP.37 It may be that the measurement
of DUP is a significant impairment to identifying and
describing any morphological changes that are linked
to it, let alone describing credible hypotheses to explain
mechanisms of biological toxicity. Limitations in our
understanding of the natural history of the illness and to our
ability to accurately identify people with FEP may make
it difficult not only to accurately measure DUP but also to
describe its mechanisms.
As previously described, the DUP is the period between
the onset of the active symptoms of psychosis (delusions,
hallucinations, or thought disorder) and the initiation of
adequate antipsychotic treatment.19 Although it appears to
be straightforward at first glance, DUP has proven to be a
difficult construct to define, measure, and operationalize,37
and there is often a great deal of inconsistency across
studies. This is because of the variability in the onset of
schizophrenia, and because a decision has to be made as to
when treatment has started.
Regarding the onset of active psychosis, some people with
schizophrenia have a difficult-to-define onset that begins
many years previously without clear psychotic symptoms,
whereas others have good preservation of personality and
functioning followed by an acute onset. Morphological
changes in the brain may be associated with the type of
onset, such that people with an insidious onset may be more
likely to show structural abnormalities. Measuring the start
date for patients with acute-onset psychosis is much easier
than for those with an insidious onset. This may lead to an
The Canadian Journal of Psychiatry, Vol 59, No 10, October 2014 W 515
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underestimate of the length of the DUP in patients with
insidious-onset psychosis, thereby decreasing our ability to
measure the link between DUP and morphological changes
in the brain. However, even if it were possible to accurately
measure the date of onset of psychosis in the insidious group,
it may be that this does not measure the onset of illness, and
consequently does not measure the start of morphological
changes in the brain. One approach to dealing with this
issue has been to measure the DUI rather than the DUP,
which attempts to measure when psychiatric problems
actually start. The difficulty that arises with this approach
is that, retrospectively, there are numerous symptoms that
may or may not be truly prodromal, and because of this
we introduce measurement error. A further problem is that
prodromal symptoms may be linked to factors that increase
the risk of psychosis rather than the disease process itself,
and untangling this may be just as problematic.
Similar to the issues of dating the onset of the illness, there
are issues about deciding when the illness is first treated.
Generally, the end point of DUP–DUI is the initiation
of adequate antipsychotic treatment. However, there is
currently no hard-and-fast rule as to what constitutes
adequate antipsychotic treatment, but the standard definition
is typically treatment with an antipsychotic for a period of
1 month. Ignoring the problems with knowing whether
someone has actually taken the drug for a month, it is
unclear whether initiating treatment ceases brain changes,
or which treatments may have an impact. There have been
arguments that just as there are many different facets to
psychosis, there are similarly many different treatments,
such as cognitive-behavioural therapy, which have been
shown to have some benefit, as well as social interventions,
such as work and housing, which have an important impact
on prognosis. Therefore, if we are actually going to use the
initiation of adequate treatment as a meaningful end point,
it may need to have a broader conceptualization.

Conclusions

There is some evidence to suggest that the DUP may have
a neurotoxic effect on brain structures in FEP. Given the
current limitations of the literature, many researchers have
been prudent in what seems a reluctance to speculate on
which mechanisms may be involved in the neurotoxicity
of untreated psychosis. Dopaminergic (catecholaminergic)
hyperactivity and prolonged HPA activation have been
hypothesized as potential mechanisms to explain these
associations, and the question remains as to whether the
observed structural changes are permanent or may be
reversed via antipsychotic treatment.
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